Article: Maternal Nicotinamide Riboside Protects Against Cardiac Mitochondrial Dysfunction and Supports Fetal Growth: Preclinical Findings

PrevNext
Cardiovascular Health Preclinical Reproductive Health

Maternal Nicotinamide Riboside Protects Against Cardiac Mitochondrial Dysfunction and Supports Fetal Growth: Preclinical Findings

Synopsis

Gestational hypoxia reduces fetal growth and impairs heart and placental mitochondrial function, partly by limiting NAD+ and energy production. In this study, pregnant guinea pigs were exposed to low oxygen late in gestation and given nicotinamide riboside (NR), an NAD+ precursor. Hypoxia reduced fetal body weight and disrupted mitochondrial function in the fetal heart, including lower complex IV activity, Sirt3 activity, and ATP levels, as well as increased mitochondrial protein acetylation. Maternal NR treatment restored NAD+ levels in the placenta, normalized fetal heart mitochondrial function and ATP production, and prevented growth restriction. These findings show that maternal NR supplementation can reverse mitochondrial dysfunction in hypoxic fetal hearts.

Journal

Reproductive Sciences

Share

Read more

Ataxia Telangiectasia

Nicotinamide Riboside Supplementation Improves Motor Coordination and Eye Movements in Children with Ataxia Telangiectasia: Clinical Findings

Objectives To examine the safety and efficacy of long-term NR supplementation on neuromotor function in patients with ataxia telangiectasia (AT). Journal Movement Disorders Key Outcomes Long-ter...

Read more
Cardiovascular Disease

Raising NAD+ via Nicotinamide Riboside Enhances Heart Function in Heart Failure: Preclinical Findings

SynopsisBoosting cellular NAD⁺ levels has been shown to prevent heart problems in various models of heart failure, but how it works at the molecular level is not fully understood. Most studies focu...

Read more